LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Microbiologics Launches SARS-CoV-2 Whole Virus Antigen Controls for Point-of-Care COVID-19 Diagnostics

By LabMedica International staff writers
Posted on 02 Sep 2021
Print article
Image: Microbiologics Launches SARS-CoV-2 Whole Virus Antigen Controls for Point-of-Care COVID-19 Diagnostics (Photo courtesy of Microbiologics, Inc.)
Image: Microbiologics Launches SARS-CoV-2 Whole Virus Antigen Controls for Point-of-Care COVID-19 Diagnostics (Photo courtesy of Microbiologics, Inc.)
Microbiologics, Inc. (Saint Cloud, MN, USA) has launched a new SARS-CoV-2 quality control (QC) product designed for use with antigen point-of-care (POC) methods.

The inactivated SARS-CoV-2 Whole Virus Antigen Control is highly concentrated with fully intact genomic and viral proteins, making it suitable for both antigen tests and nucleic acid amplification tests (NAATs). It serves as a non-viable, external, positive control to evaluate the assay’s performance and mitigate the potential for false negative or false positive results. In NAAT applications, the control tests the full process including extraction, amplification and detection. In antigen-based applications, the high titer formula provides a clear positive reaction to monitor the detection of SARS-CoV-2 viral antigens.

Rapid POC antigen test methods for SARS-CoV-2 have become widely adopted during the COVID-19 pandemic due to capacity limitations and supply shortages for laboratory-based molecular methods. Antigen tests are also relatively inexpensive and provide a quicker time to result, making them ideal for instances where turnaround time is particularly critical, such as congregate housing settings and school health clinics. The SARS-CoV-2 Whole Virus Antigen Control is the latest addition to Microbiologics’ extensive offering of In Vitro Diagnostic (IVD) quality controls and Research Use Only (RUO) materials designed to support the ongoing efforts to combat the COVID-19 pandemic. Microbiologics offers their SARS-CoV-2 Whole Virus Antigen Control in a kit containing 6 individually packaged lyophilized swabs. Routine use of quality controls monitors test variation, lot-to-lot test kit performance, operator performance and aids in identifying random or systemic error.

“Our SARS-CoV-2 Whole Virus Antigen Control comes in a foam nasopharyngeal (NP) swab format similar to patient sample collection devices commonly used for COVID-19 testing,” shared Brian Beck, PhD., Microbiologics Vice President of Research and Development. “We have confirmed the compatibility of our controls on multiple systems which allows users more flexibility.”

Related Links:
Microbiologics, Inc.

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.